John Michael Lawrie
Management
Yes, NHS is -- we don't talk about this too much, but I mean, it is remarkable and I give the team, the industry team that runs this, just enormous credit. And this thing cost us billions, and we're now making money in NHS. And we've taken, I think, correct me, I don't have it on the tip of my tongue, but another 4, 5 trusts live. And we are making money on those trusts. We are making money. And the significance of what we talked about today is that when we renegotiated the contract, we sort of gave up our exclusivity with the region that we had been awarded by NHS. In exchange for that, we asked the right to compete throughout the U.K. And this Bristol NHS trust, which is a large trust, was taken away from a competitor. This is our first major win outside of that region, where we had been given some preferential treatment. What I mean by preferential treatment, NHS subsidized the cost of the system. So this one, we won straight up, no subsidy from NHS, just won on the merits. So the project hasn't started yet. It was just awarded. But our anticipation is, yes, we can make money at it because we have now delivered the Lorenzo product suites. They're up, they're running, they're working, and there's very little additional development work that needs to be done for these new trusts that we are bidding on and winning. So it's quite a turnaround in NHS. Even the press in the U.K. has actually turned positive around some of these things, which, in and of itself, is remarkable.